Our team of passionate oncology experts, HRW OR:BIT, provide deep scientific, commercial, and behavioural understanding of the global oncology landscape: helping oncology brands succeed in benefiting more patients and improving lives.
We understand our clients need a truly collaborative and specialist oncology partner to address oncology market research complexities, who can:
• Fully grasp the market context and landscape for oncology products, e.g., when a drug has multiple tumour indications and messages/strategies that will impact on each other
• Provide materials reflecting depth and clarity of understanding, e.g., with language that reflects the potential licensed indication or line of therapy for the oncology product in question
• Conduct interviews with moderators who understand the specifics of the product, e.g.’ the logistical steps needed for CAR-T cell therapy administration versus standard stem cell transplant or monoclonal antibodies
• Help find the right respondents e.g., treaters of rare cancers, CAR-T specialists, or metastatic cancer patients, with a lengthy project recruit and fieldwork time
The complexity of oncology as a pharmaceutical therapy area and the speed of its evolution makes it exciting and highly competitive.
HRW’s Oncology Research: Business Insights Team (OR:BIT) are recognised as industry-leading experts for the breadth of their oncology expertise.
Our knowledge spans a multitude of malignancies – from rare solid tumours to haematologic malignancies – couple with a strong understanding of established and novel treatment modalities.
We combine our deep oncology and behavioural science knowledge to provide rich insights and clear strategic recommendations for tackling the issues and barriers our oncology clients face.
Marianne holds a bachelor’s degree in pharmacology and a post graduate diploma in microbiology and immunology. She moved from industrial pharmacy to market research in 2012 and found her passion in oncology. The rapidly evolving oncology landscape fascinates her, fulfils her thirst for knowledge and it fills her with hope to see better outcomes offered to patients every day. Marianne specialises in solid tumours and has also worked across multiple haematological malignancies. ASCO and ESMO weeks are her best weeks of the year.
Having joined HRW in 2009, and leveraging a degree in history that leaned heavily into story driven communication, a career in market research seemed like the perfect fit for Kirsty. With the launch of OR:BIT in 2016, she was enthusiastic to join the team and take the opportunity to develop an academic interest in the complex and evolving science of the Oncology space. Kirsty’s particular passion lies in patient research, and having the opportunity to get close to a multitude of different patients, to learn about their experiences and hear first-hand about their challenges and hopes surrounding living with, or dying from, cancer is inspirational. Her core areas of specialism include NSCLC, myeloma, head and neck, prostate and haematological malignancies such as AML, CML and CLL.
Sophie developed her interest in oncology during her MSci in biochemistry, in particular studying cancer immunotherapies. She joined HRW in 2016, pursuing her interest in oncology and discovering a passion for patient research. Sophie has expertise across multiple solid tumour and haematological cancers, ranging from the most common types to rare cancers, and is always looking for new opportunities to connect with cancer patients.
Victoria started in pharmaceutical market research in 2013, initially focusing on chronic conditions and mental health. Her experience in oncology developed over time starting in 2017 and has grown to include research in solid tumor types (e.g., prostate and breast cancer) and hematological malignancies (acute myeloid leukemia, multiple myeloma). She has a keen interest in listening to patient stories and exploring opportunities to make their experience better. She is currently pursuing her Master’s in Public Health, concentrating on Health Policy and Management.
Liz came into market research with a background in strategic communication and a graduate degree in Advertising, where her research focused on activating health behavior changes in underserved populations. She been involved in oncology market research for the past decade, supporting brand development at various stages of their life cycle from foundational journey and launch, through expanding indications & portfolio strategy, all the way through patent extension. A seasoned moderator, Liz has led & conducted thousands of interviews with patients, caregivers, physicians, nurses, and other key stakeholders. She has wide-ranging experience with immune-oncology agents & targeted therapies across a range of solid tumors, in both metastatic and adjuvant settings. In particular, Liz has enjoyed her work in breast cancer, urothelial carcinoma, and developing pan-tumor strategy.
With a background in psychology and business, Alex loves putting her curiosity to work exploring human behavior to build strong brands. She fell in love with the pharma industry from the start but knew she was home when she did her first oncology project over a decade ago. Since then, she’s focused heavily on Oncology, specializing in solid tumors with a particular interest in targeted therapies and rare malignancies. Alex loves exploring the complex realities of those living with and treating cancer in order to help her clients empathize and navigate this space as they bring live changing solutions to market.
Jessica joined HRW in 2022 after completing her MSc in Cognitive and Clinical Neuroscience from Brunel University London. Throughout her degree, she worked as a research assistant where she a focused her research on attention and perception which are immensely important parts of human psychology. She has also always had an immense passion for oncology research and frequently takes part in the Cancer Research UK London Winter Run every year to show her support. After join HRW, she very quickly learnt there was an opportunity to grow her knowledge and passion in oncology research and hopes to bring her science expertise to the team.
Oliver joined HRW in 2022 after completing an MSc in Health Behaviour Change from UCL. His background is in customer insights and behavioural science, having worked with clients across healthcare, higher education and the third sector for over a decade. After joining HRW, he quickly specialised in oncology research with physicians, patients and payers across a broad range of tumour types and indications. This expertise gives Ollie a robust understanding of the oncology landscape to leverage when thinking about behavioural drivers critical to meeting your strategic needs.
Our client wanted to ensure that their prostate cancer treatment was sufficiently differentiated from competitors in a crowded marketplace, creating a compelling story to convince HCPs that it is the best treatment available to use:
Our client was working toward developing a comprehensive bladder cancer portfolio. Foundational research was required to understand the complete patient journey across the bladder cancer space (non-muscle invasive, muscle invasive and metastatic) to identify unmet needs and pain points to develop communications and value add service to optimise opportunities for their portfolio of products.
A global client wanted to inform the medicine development strategy for a new treatment in the SCCHN space, in both the loco-regionally advanced, locally recurrent and metastatic setting. This research comprised two phases:
Phase 1: Loco-regionally advanced and locally recurrent
Phase 2: Metastatic (de novo/relapsed)
Blogs, News, and Insights
A User Guide: How To Live With Epilepsy
My name is Kirsty Page, and I have epilepsy. It does seem somewhat dramatic to say it out loud like that; it feels...
Generative AI in Healthcare Market Research
Among the many use cases proposed at conferences and in articles by industry personnel over the past year, one such idea...
Sharing is Caring: The Future of Decision Making
As ASCO this year pursued the theme of “partnering with patients,” it was clear in the abstract submission and selec...
The Chatbot: Using AI in Market Research Methodologies
Let’s have a chat
We’re all talking about it! The launch of open AI platforms like ChatGPT has caused much exci...
Schizophrenia: Our Multi-Faceted Approach to Recruiting Hard to Reach Patient Populations
24th May represents World Schizophrenia Awareness Day- which is a day dedicated to raising awareness for a mental health...
Endometaverse: Doctors and Patients in the Market Research Metaverse
HRW Innovation has recently conducted a pioneering first-of-its-kind study exploring endometriosis with both patients an...
Ideas that Stick: Why Liking and Appeal can Lead us Astray when Developing Concepts
Delivering the right concept for your brand is essential to gain consideration and keep your business top-of-mind, and s...
Politics, Prevention, and Pride: Evolution of the Vaccines Discourse on Twitter over the Pandemic
Earlier this year, we undertook research using the Relative Insights platform to highlight key trends in public discours...
Innovation Trends: What’s Come Before and What’s Next
For the last 22 years, HRW has been committed to checking out the latest innovations and technologies with a critical ey...
OR:BIT CAR-T webinar highlights
Enjoy viewing our short video message, with key highlights and insights shared by five global specialists.
To find out m...
Episode 3: Music and Alzheimer’s Disease
Music and its potential therapeutic effects have been of interest in various research fields, especially in patients dia...
Episode 1: Biomarkers in Oncology
The interplay between targeted therapy and a patient’s expression of specific biomarkers is an important aspect to con...
checkedI would like to receive news and information from HRW
© Copyright HRW 2023
Designed in the UK by Yellowball.